NCT03004001View on ClinicalTrials.gov

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Nephrotic Syndrome
Interventions
DRUG

Alirocumab

150 mg biweekly

DRUG

Alirocumab placebo

placebo

DRUG

Atorvastatin

20 mg/day

Trial Locations (1)

75216

DallasVAMC, Dallas

Sponsors

Collaborators (1)

Aventis Pharmaceuticals
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

Gloria Vega

FED